Alpha CognitionACOG -1.18%31 EV-to-EBITDA is -5.02 as of Jul. 12, 2026. GuruFocus rates ACOG with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 391 Biotechnology companies, Alpha Cognition ranks worse than 255754.22% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alpha Cognition's enterprise value is $135.49 Mil.
Alpha Cognition's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-26.96 Mil. Therefore, Alpha Cognition's EV-to-EBITDA for today is -5.02.
The historical rank and industry rank for Alpha Cognition's EV-to-EBITDA or its related term are showing as below:
ACOG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.67 Med: -3.63 Max: -1.92
Current: -5.02
During the past 6 years, the highest EV-to-EBITDA of Alpha Cognition was -1.92. The lowest was -10.67. And the median was -3.63.
ACOG's EV-to-EBITDA is ranked worse than 100% of 391
companies
in the Biotechnology industry
Industry Median: 13.14
vs ACOG: -5.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alpha Cognition's PE Ratio (TTM) for today is calculated as:
Alpha Cognition's share price for today is $8.41.
Alpha Cognition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.590.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Alpha Cognition's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alpha Cognition's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Cognition EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Cognition's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alpha Cognition's EV-to-EBITDA falls into.
Alpha Cognition's current Enterprise Value is $135.49 Mil.
Alpha Cognition's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Cognition (ACOG) has a EV-to-EBITDA of -5.02 as of Jul. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alpha Cognition. According to the industry distribution chart, Alpha Cognition ranks #999999 out of 391 companies in the Biotechnology industry.
Is Alpha Cognition's EV-to-EBITDA too high?
Alpha Cognition's current EV-to-EBITDA is -5.02. Based on the distribution chart, Alpha Cognition ranks #999999 out of 391 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alpha Cognition has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Cognition's EV-to-EBITDA compare to HURA and MENS?
According to the Biotechnology industry distribution chart, Alpha Cognition ranks #999999 out of 391 companies for EV-to-EBITDA. This places Alpha Cognition in the lower half of its industry. The industry median EV-to-EBITDA is 13.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.14, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alpha Cognition. For the Biotechnology industry, the median EV-to-EBITDA is 13.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Cognition's current EV-to-EBITDA is -5.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Cognition stock overvalued right now?
Alpha Cognition (ACOG) has a current EV-to-EBITDA of -5.02. The current EV-to-EBITDA is -5.02. Alpha Cognition's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alpha Cognition (ACOG), the current EV-to-EBITDA is -5.02 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
31GF Score
Get the complete analysis for ACOG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACOG has been successfully added to your 
